ASH Clinical News ACN_5.3_web | Page 11

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN Guidelines®) recommend enasidenib (IDHIFA) in R/R AML with an IDH2 mutation 1
Learn more at
IDHIFApro.com/explore
receiving IDHIFA, or male patients with pregnant female
partners should be apprised of the potential risk to the fetus.
ADVERSE REACTIONS
• The most common adverse reactions (≥20%) included
total bilirubin increased (81%), calcium decreased (74%),
nausea (50%), diarrhea (43%), potassium decreased
(41%), vomiting (34%), decreased appetite (34%), and
phosphorus decreased (27%)
• The most frequently reported ≥Grade 3 adverse reactions
(≥5%) included total bilirubin increased (15%), potassium
decreased (15%), phosphorus decreased (8%), calcium
decreased (8%), diarrhea (8%), differentiation syndrome
(7%), non-infectious leukocytosis (6%), tumor lysis syndrome
(6%), and nausea (5%)
• Serious adverse reactions were reported in 77.1% of
patients. The most frequent serious adverse reactions
(≥2%) were leukocytosis (10%), diarrhea (6%), nausea
(5%), vomiting (3%), decreased appetite (3%), tumor
lysis syndrome (5%), and differentiation syndrome (8%).
Differentiation syndrome events characterized as serious
included pyrexia, renal failure acute, hypoxia, respiratory
failure, and multi-organ failure
LACTATION
Many drugs are excreted in human milk and because of the
potential for adverse reactions in breastfed infants, advise
women not to breastfeed during treatment with IDHIFA and
for at least 1 month after the last dose.
Reference: 1. Referenced with permission from the NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.1.2018.
© National Comprehensive Cancer Network, Inc. 2018. All rights reserved.
Accessed February 13, 2018. To view the most recent and complete version of the
guideline, go online to NCCN.org. The National Comprehensive Cancer Network
makes no warranties of any kind whatsoever regarding their content, use or
application and disclaims any responsibility for their application or use in any way.
Please see brief summary of full Prescribing Information,
including Boxed WARNING, on the following pages.
IDHIFA ® is a registered trademark of Celgene Corporation.
IDHIFA ® is licensed from Agios Pharmaceuticals, Inc.
© 2018 Celgene Corporation 02/18 US-IDH180008